Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps

Diabetes Technology and Therapeutics

Volumn 9, Issue 6, 2007, Pages 517-521

  Senstius, Jakob ^a   Poulsen, Christian ^a   Hvass, Aage ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; INSULIN ASPART; INSULIN GLULISINE; PROTEIN;

ARTICLE; COMPARATIVE STUDY; DRUG STABILITY; FLOW RATE; INSULIN INFUSION; MOLECULAR WEIGHT; PRIORITY JOURNAL; SIMULATION; TEMPERATURE;

DRUG STABILITY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 36349005313     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2007.0233     Document Type: Article

References (15)

1. Radermecker RP, Scheen AJ: Continuous subcutaneous insulin infusion with short acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004;20:178-188.
2. Guerci B, Sauvanet JP: Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab 2005;31:4S7-4S24.
3. Hanaire-Broutin H, Schumicki D-M, Hoogma RPL, Souhami E: Safety of insulin glulisine compared with insulin aspart administered by continuous subcutaneous insulin infusion (CSII) [abstract]. Diabetes 2004;53(Suppl 2):A4.
4. Brange J: Stability of Insulin. Studies on the Physical and Chemical Stability of Insulin in Pharmaceutical Formulation. Boston: Kluwer Academic Publishers, 1994.
5. Brange J, Hallund O, Sorensen E: Chemical stability of insulin: 5. Isolation, characterization and identification of insulin transformation products. Acta Pharm Nord 1992;4:223-232.
6. Robbins DC, Cooper SM, Fineberg SE, Mead PM: Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 1987;36:838-841.
7. Maislos M, Mead PM, Gaynor DH, Robbins DC: The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin. J Clin Invest 1986;77:717-723.
8. API-BH-19156-1: Prescribing Information for Apidra [leaflet]. Paris: Aventis Pharmaceuticals, 2005.
9. Summary of Product Characteristics, Annex 1 "Novo-Rapid 100 U/ml." Available at: http://www.emea.eu.int/humandocs/Humans/EPAR/ novorapid/novorapid.htm (accessed February 16, 2006).
10. Senstius J, Poulsen C, Hvass A: Comparison of invitro stability at needle end of insulin aspart and insulin glulisine during simulated use in infusion pumps [abstract]. Diabetes 2006;55:A455.
11. DeFelippis MR, Bell MA, Heyob JA, Storms SM: In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther 2006;8:358-368.
12. Senstius J, Harboe E, Westermann H: In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed® 508 insulin pump. Diabetes Technol Ther 2007;9:75-79.
13. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL: Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001;40:6036-6046.
14. Jars MU, Hvass A, Waaben D: Insulin aspart (Asp(B28) human insulin) derivatives formed in pharmaceutical solutions. Pharm Res 2002;19:621-628.
15. Mollmann SH, Elofsson U, Bukrinsky JT, Frokjaer S: Displacement of adsorbed insulin by Tween 80 monitored using total internal reflection fluorescence and ellipsometry. Pharm Res 2005;22:1931-1941.